We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.
- Authors
Sengar, Manju; Chorghe, Siddhesh; Jadhav, Kamini; Singh, Shikha; Laskar, Sarbani Ghosh; Pai, Prathamesh; Aggarwal, Jai Prakash; D'Cruz, Anil; Chaturvedi, Pankaj; Deshpande, Mandar; Chaukar, Devendra; Budrukkar, Ashwini; Gupta, Tejpal; Murthy, Vedang; Kane, Shubhada; Thakur, Meenakshi; Rangarajan, Venkatesh; Kannan, Sadhana; Shet, Tanuja; Kode, Jyoti
- Abstract
ABSTRACT Background The purpose of this study was to explore urinary Epstein-Barr virus (EBV)-DNA as a potential biomarker in patients with nasopharyngeal carcinoma (NPC). Methods EBV-DNA copies were estimated in plasma/urine of patients with NPC ( n = 76) by real-time polymerase chain reaction (PCR) at baseline, during therapy, and at follow-up. Their correlation with EBV-RNA expression in tissues ( n = 53) was used to assess sensitivity and specificity of plasma/urine EBV-DNA. Correlation of urine and plasma EBV-DNA with each other and with radiological response was evaluated. Results This study demonstrated that urine EBV-DNA has high sensitivity (96%) at diagnosis and it correlates well with plasma EBV-DNA at baseline and after neoadjuvant chemotherapy. The EBV-DNA copies reduced significantly with therapy (plasma: p < .001; urine: p = .011). Patients with low EBV-DNA copies demonstrated improved survival (plasma: p = .023; urine: p = .083). Conclusion Plasma EBV-DNA is a good prognostic marker, whereas further study on a larger cohort may help in developing urine EBV-DNA as a surrogate prognostic marker for patients with NPC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1666-E1673, 2016
- Subjects
NASOPHARYNX cancer; TUMOR markers; DNA analysis; DIAGNOSTIC use of in-situ hybridization; POSITRON emission tomography
- Publication
Head & Neck, 2016, Vol 38, pE1666
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.24297